Highlights

  • Neuren reported A$42.7 million of Revenue and A$4.9 million of net profit after tax for the half-year ended 30 June 2026.
  • DAYBUE Royalty income was US$23.3 million, while cash and investments stood at A$287 million.
  • The board declared Neuren’s first Dividend at 15 cents per share, fully franked, with payment scheduled for 7 October 2026.
  • Clinical Investment increased as NNZ-2591, also known as ercanetide, progressed through the Phase 3 Koala study.
  • European commercialisation of trofinetide and further clinical milestones remain important items on the 2026 calendar.

Neuren Pharmaceuticals Limited (ASX:NEU) is a biopharmaceutical company developing new drug therapies for serious neurological conditions caused by genetic abnormalities or brain injury, with its shares listed on the ASX. Its 2026 half-year result shows a Business balancing commercial income from trofinetide with rising investment in its next clinical programs. Royalty receipts, a sizeable cash position and the company’s first dividend now sit alongside materially higher research spending.

2026 Earnings reflect heavier clinical investment

For the six months ended 30 June 2026, Neuren reported revenue of A$42.7 million and net profit after tax of A$4.9 million. Research and Development expenditure reached A$27.4 million, while corporate costs were A$3.0 million. The spending profile reflects the progression of the company’s clinical pipeline into more advanced stages.

Royalty income from DAYBUE was US$23.3 million. Neuren does not directly sell the medicine; trofinetide is licensed to Acadia Pharmaceuticals, which commercialises it for Rett syndrome. Neuren receives royalties and may also receive milestone payments, giving the company commercial exposure without operating the sales infrastructure itself.

First dividend alongside A$287 million liquidity

Cash and investments totalled A$287 million at 30 June 2026. The board declared a fully franked Interim Dividend of 15 cents per share, the first dividend in Neuren’s history, with payment scheduled for 7 October 2026. The decision is notable because the company continues to fund a broader development program at the same time.

NNZ-2591 advances through Phase 3

The central development program is NNZ-2591, or ercanetide. The Phase 3 Koala study in Phelan-McDermid syndrome was reported with 15 active sites and about 100 referred families. Neuren has budgeted total program costs of US$80 million to US$90 million and said spending remained on track.

A Type B End of Phase 2 meeting with the United States Food and Drug Administration for Pitt Hopkins syndrome is scheduled for late October 2026, followed by a patient-focused Drug Development meeting on 13 November 2026. Results from a Japanese trofinetide trial are expected during the September-to-November 2026 period.

European launch adds another commercial milestone

Trofinetide has received European Marketing authorisation, with a German launch expected in the early part of the fourth quarter of 2026. Neuren may receive US$35 million on the first European sale. A separate US$50 million milestone is linked to North American net sales exceeding US$500 million in a year. These payments are conditional and separate from recurring royalty income.

For 2026, Neuren guided to royalty income of US$52.6 million to US$56.2 million, based on DAYBUE net sales guidance of US$480 million to US$510 million. The relationship between royalty growth and clinical expenditure will remain central to the company’s financial profile while late-stage studies continue.

Key Insights

Neuren’s 2026 position combines an established royalty stream with a capital-intensive clinical pipeline. The first dividend shows that the board is returning part of available cash while development spending rises, but results remain linked to late-stage trial execution, regulatory processes and the commercial performance of licensed trofinetide. Upcoming milestones across Europe, Japan and the NNZ-2591 program will provide further evidence on how the business is broadening beyond its current royalty base.